Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARDX

Ardelyx Inc

Dec 01 • 04:00PM ET

4.76

Dollar change +0.25
Percentage change 5.54	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.12	Insider Own	4.05%	Shs Outstand	232.14M	Perf Week	8.68%
Market Cap	1.10B	Forward P/E	-	EPS next Y	-0.24	Insider Trans	-1.61%	Shs Float	222.73M	Perf Month	20.81%
Income	-26.57M	PEG	-	EPS next Q	-0.10	Inst Own	54.23%	Short Float / Ratio	17.12% / 5.75	Perf Quarter	-1.24%
Sales	134.27M	P/S	8.23	EPS this Y	28.73%	Inst Trans	56.04%	Short Interest	38.12M	Perf Half Y	35.23%
Book/sh	0.82	P/B	5.78	EPS next Y	19.60%	ROA	-12.24%	Target Price	9.58	Perf Year	176.74%
Cash/sh	0.71	P/C	6.69	EPS next 5Y	30.00%	ROE	-20.60%	52W Range	1.68 - 5.12	Perf YTD	67.02%
Dividend	-	P/FCF	-	EPS past 5Y	20.81%	ROI	-12.01%	52W High	-7.12%	Beta	1.04
Dividend %	-	Quick Ratio	5.35	Sales past 5Y	100.41%	Gross Margin	85.41%	52W Low	183.33%	ATR	0.25
Employees	133	Current Ratio	5.54	Sales Q/Q	1030.99%	Oper. Margin	-17.24%	RSI (14)	66.35	Volatility	5.41% 5.65%
Optionable	Yes	Debt/Eq	0.18	EPS Q/Q	120.98%	Profit Margin	-19.79%	Rel Volume	0.74	Prev Close	4.51
Shortable	Yes	LT Debt/Eq	0.16	Earnings	Oct 31 BMO	Payout	-	Avg Volume	6.62M	Price	4.76
Recom	1.00	SMA20	16.52%	SMA50	21.87%	SMA200	21.21%	Volume	4,906,677	Change	5.54%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-07-23	Initiated	H.C. Wainwright	Buy	$9
Aug-25-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$5 → $10
Mar-03-23	Upgrade	Wedbush	Neutral → Outperform	$3 → $6
Nov-17-22	Upgrade	Piper Sandler	Neutral → Overweight	$3 → $8
May-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$7 → $1
Dec-01-21	Upgrade	Ladenburg Thalmann	Neutral → Buy	$6
Oct-14-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-21-21	Downgrade	Jefferies	Buy → Hold	$11 → $2
Jul-20-21	Downgrade	Wedbush	Outperform → Neutral	$3
Jul-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$14 → $4
Mar-23-21	Initiated	Wedbush	Outperform	$14
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight	$14
Oct-20-20	Resumed	Citigroup	Buy	$13
Feb-18-20	Resumed	Jefferies	Buy	$11
Feb-12-20	Initiated	Citigroup	Buy	$13
Feb-10-20	Initiated	Cowen	Outperform
Apr-08-19	Initiated	Piper Jaffray	Overweight	$15
Aug-24-18	Initiated	Jefferies	Buy	$7
Mar-19-18	Resumed	Leerink Partners	Outperform	$13
Nov-29-17	Reiterated	Citigroup	Buy	$16 → $17

Show Previous Ratings

Nov-21-23 04:02PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
09:37AM	7 Penny Stocks Youll Regret Not Buying Soon: November 2023 (InvestorPlace)
08:01AM	Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-17-23 09:00AM	Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia (Zacks) +7.44%
Nov-15-23 04:02PM	XPHOZAH (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia (GlobeNewswire)
04:02PM	Loading…
Nov-13-23 04:02PM	Ardelyx Announces Departure of Board Member (GlobeNewswire) +5.62%
Nov-10-23 08:05AM	Ardelyx to Participate at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-23 08:00AM	Ardelyx Announces XPHOZAH (tenapanor) Now Available in the United States (GlobeNewswire)
Nov-03-23 08:00AM	Ardelyx Shares Positive Data from Studies of XPHOZAH (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023 (GlobeNewswire)
Nov-02-23 09:40AM	Are Medical Stocks Lagging Arcellx (ACLX) This Year? (Zacks)
Nov-01-23 10:42AM	Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 11:15PM	Q3 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) +9.12%
05:09PM	Why Ardelyx Stock Soared Today (Motley Fool)
08:40AM	Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates (Zacks)
07:29AM	Ardelyx: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA Net Sales Revenue Guidance (GlobeNewswire)
Oct-30-23 05:42PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Oct-23-23 08:07AM	Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023 (GlobeNewswire)
Oct-19-23 10:21AM	Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia (Zacks) -7.03%
Oct-18-23 04:31PM	Why Ardelyx Stock Popped Today (Motley Fool) +13.33%
04:02PM	Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023 (GlobeNewswire)
10:42AM	FDA Sends ARDX Stock Soaring After Approving Ardelyx's Kidney Disease Drug (InvestorPlace)
Oct-17-23 07:24PM	UPDATE 2-US FDA approves Ardelyx's kidney disease-related drug (Reuters)
07:23PM	Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital (GlobeNewswire)
07:06PM	US FDA approves Ardelyx's kidney disease-related drug (Reuters)
07:01PM	FDA Approves XPHOZAH (tenapanor), a First-in-Class Phosphate Absorption Inhibitor (GlobeNewswire)
Oct-13-23 08:00AM	Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA (GlobeNewswire)
Oct-11-23 04:17PM	Why Shares of Ardelyx Were Down Wednesday (Motley Fool) -14.49%
Oct-04-23 08:00AM	Ardelyx Shares Preliminary Data on Use of IBSRELA (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023 (GlobeNewswire)
Sep-28-23 08:02AM	Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility (GlobeNewswire)
04:15AM	Loading…
Sep-25-23 04:15AM	Tenapanor for Hyperphosphatemia Approved in Japan (GlobeNewswire)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-11-23 08:00AM	Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023 (GlobeNewswire)
Sep-08-23 08:00AM	Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-07-23 08:00AM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Sep-06-23 12:36PM	Is Ardelyx (ARDX) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
12:13PM	Unraveling Ardelyx Inc (ARDX): A Deep Dive into Its Performance Metrics (GuruFocus.com)
Aug-30-23 01:02PM	The 3 Most Promising Penny Stocks to Own Now (InvestorPlace)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey) +7.87%
Aug-26-23 03:17PM	3 Penny Stocks Youll Regret Not Buying Soon (InvestorPlace)
Aug-25-23 09:42AM	Netflix upgraded, Olaplex downgraded: Wall Street's top analyst calls (The Fly) +12.25%
Aug-24-23 11:05AM	Dont Sleep on These 3 Penny Stocks That Will Mint Millionaires (InvestorPlace)
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey) -5.65%
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Aug-04-23 08:29AM	Ardelyx, Inc. (NASDAQ:ARDX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 08:26AM	Forecast: Analysts Think Ardelyx, Inc.'s (NASDAQ:ARDX) Business Prospects Have Improved Drastically (Simply Wall St.)
Aug-02-23 08:35AM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.21%
07:26AM	Ardelyx: Q2 Earnings Snapshot (AP Finance)
07:00AM	Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance (GlobeNewswire)
Jul-27-23 04:05PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Jul-26-23 07:55AM	Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jul-20-23 04:05PM	Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference (GlobeNewswire)
Jul-16-23 09:37AM	Loss-Making Ardelyx, Inc. (NASDAQ:ARDX) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Jul-13-23 08:00AM	Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China (GlobeNewswire)
Jun-29-23 04:09PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Jun-19-23 08:00AM	Top Penny Stocks for Q3 2023 (Investopedia)
Jun-08-23 09:48AM	Ardelyx (NASDAQ:ARDX) shareholder returns have been incredible, earning 430% in 1 year (Simply Wall St.)
Jun-05-23 08:00AM	Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase (GlobeNewswire)
May-31-23 08:00AM	Ardelyx to Present at the Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-23-23 04:05PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
May-22-23 03:30PM	Ardelyx Insiders Land Bargain With Gains Of US$1.1m \ (Simply Wall St.)
May-17-23 07:30AM	Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) (GlobeNewswire) -11.88%
May-15-23 04:05PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
May-09-23 08:00AM	Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults (GlobeNewswire)
May-06-23 10:08AM	Retail investors account for 60% of Ardelyx, Inc.'s (NASDAQ:ARDX) ownership, while institutions account for 38% (Simply Wall St.)
May-05-23 08:28AM	10 Best Stocks To Buy For A Stock Market Game (Insider Monkey)
May-04-23 09:52AM	Q1 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:15PM	Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.41%
04:02PM	Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 08:00AM	Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference (GlobeNewswire)
Apr-26-23 08:00AM	Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor) (GlobeNewswire)
Apr-17-23 08:50AM	Getting In Cheap On Ardelyx, Inc. (NASDAQ:ARDX) Is Unlikely (Simply Wall St.)
Apr-13-23 04:05PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire) +6.22%
Apr-12-23 04:05PM	Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings (GlobeNewswire)
Apr-11-23 08:29AM	3 Penny Stocks to Add to Your Watchlist for Potential Breakouts (InvestorPlace) +7.98%
Apr-07-23 07:30AM	7 A-Rated Stocks to Buy for April 2023 (InvestorPlace)
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
Mar-28-23 03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-17-23 06:15PM	Ardelyx (ARDX) Gains As Market Dips: What You Should Know (Zacks)
Mar-13-23 06:30AM	7 Core Stocks to Build a Solid Portfolio Around (InvestorPlace)
Mar-08-23 02:50PM	Top Healthcare Stocks for March 2023 (Investopedia)
Mar-04-23 07:02AM	Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher (Simply Wall St.)
Mar-03-23 03:34PM	Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story (Benzinga) +32.18%
07:52AM	Q4 2022 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 05:25PM	Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:02PM	Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-23 08:00AM	Ardelyx Publishes First Environmental, Social and Governance (ESG) Report (GlobeNewswire)
06:30AM	7 Smart Stock Picks for Cautious Investors (InvestorPlace)
Feb-27-23 08:15AM	Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-23-23 08:00AM	Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023 (GlobeNewswire)
Feb-22-23 06:15PM	Ardelyx (ARDX) Gains As Market Dips: What You Should Know (Zacks)
Feb-20-23 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Feb-19-23 02:05PM	7 A-Rated Penny Stocks Worth Betting On (InvestorPlace)
Feb-17-23 06:30AM	7 Stocks Under $10 to Buy in February (InvestorPlace)
Feb-15-23 06:15PM	Ardelyx (ARDX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:56AM	Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store? (Zacks)
Feb-12-23 10:56AM	7 A-Rated Healthcare Stocks to Buy for the Future of Medicine (InvestorPlace)
Feb-09-23 06:15PM	Ardelyx (ARDX) Gains As Market Dips: What You Should Know (Zacks)

Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenbaum David P.	Chief Development Officer	Nov 30	Sale	4.50	3,000	13,500	359,543	Dec 01 04:47 PM
RAAB MICHAEL	President & CEO	Nov 20	Sale	4.36	11,368	49,589	867,868	Nov 22 05:19 PM
Rodriguez Susan	Chief Commercial Officer	Nov 20	Sale	4.36	4,714	20,563	346,973	Nov 22 05:20 PM
Renz Justin A	Chief Financial Officer	Nov 20	Sale	4.36	2,873	12,533	332,426	Nov 22 05:20 PM
Blanks Robert	See Remarks	Nov 20	Sale	4.36	2,835	12,367	260,453	Nov 22 05:17 PM
Rosenbaum David P.	Chief Development Officer	Nov 20	Sale	4.36	2,835	12,367	362,543	Nov 22 05:21 PM
Williams Laura A	Chief Medical Officer	Nov 20	Sale	4.36	2,581	11,259	266,191	Nov 22 05:22 PM
GRAMMER ELIZABETH A	See Remarks	Nov 20	Sale	4.36	2,384	10,399	325,675	Nov 22 05:19 PM
Felsch Robert Ora	See Remarks	Nov 20	Sale	4.36	1,044	4,554	117,066	Nov 22 05:18 PM
Rosenbaum David P.	Chief Development Officer	Nov 20	Sale	4.36	932	4,066	113,293	Nov 22 05:21 PM
Williams Laura A	Chief Medical Officer	Nov 15	Sale	4.00	25,000	99,998	266,839	Nov 17 05:30 PM
Rosenbaum David P.	Chief Development Officer	Oct 10	Sale	4.00	1,644	6,576	365,378	Oct 12 05:09 PM
Rosenbaum David P.	Chief Development Officer	Sep 08	Sale	4.55	2,897	13,181	367,022	Sep 12 05:24 PM
RAAB MICHAEL	President & CEO	Aug 21	Sale	3.55	11,419	40,558	876,236	Aug 23 04:41 PM
Rodriguez Susan	Chief Commercial Officer	Aug 21	Sale	3.55	4,733	16,811	348,687	Aug 23 04:48 PM
Renz Justin A	Chief Financial Officer	Aug 21	Sale	3.55	2,884	10,243	333,849	Aug 23 04:42 PM
Rosenbaum David P.	Chief Development Officer	Aug 21	Sale	3.55	2,846	10,108	369,919	Aug 23 04:45 PM
Blanks Robert	See Remarks	Aug 21	Sale	3.55	2,846	10,108	263,288	Aug 23 04:36 PM
Williams Laura A	Chief Medical Officer	Aug 21	Sale	3.55	2,591	9,203	291,839	Aug 23 04:46 PM
GRAMMER ELIZABETH A	See Remarks	Aug 21	Sale	3.55	2,392	8,496	328,059	Aug 23 04:39 PM
Felsch Robert Ora	See Remarks	Aug 21	Sale	3.55	1,048	3,722	115,110	Aug 23 04:38 PM
Rosenbaum David P.	Chief Development Officer	Aug 21	Sale	3.55	937	3,328	111,225	Aug 23 04:45 PM
Williams Laura A	Chief Medical Officer	Jun 27	Sale	3.35	25,000	83,632	294,430	Jun 29 07:22 PM
Blanks Robert	See Remarks	Jun 23	Option Exercise	3.42	33,333	113,999	299,467	Jun 27 06:40 PM
Blanks Robert	See Remarks	Jun 23	Sale	3.63	33,333	121,042	266,134	Jun 27 06:40 PM
RAAB MICHAEL	President & CEO	May 23	Sale	3.65	11,357	41,489	887,655	May 25 08:55 AM
Rodriguez Susan	Chief Commercial Officer	May 23	Sale	3.65	4,711	17,210	353,420	May 25 08:52 AM
Renz Justin A	Chief Financial Officer	May 23	Sale	3.65	2,873	10,496	336,733	May 25 08:53 AM
Rosenbaum David P.	Chief Development Officer	May 23	Sale	3.65	2,835	10,357	372,765	May 25 08:52 AM
Blanks Robert	See Remarks	May 23	Sale	3.65	2,835	10,357	266,134	May 25 08:54 AM
Williams Laura A	Chief Medical Officer	May 23	Sale	3.65	2,583	9,436	319,430	May 25 08:51 AM
GRAMMER ELIZABETH A	See Remarks	May 23	Sale	3.65	2,384	8,709	330,451	May 25 08:54 AM
Felsch Robert Ora	See Remarks	May 23	Sale	3.65	1,046	3,821	116,158	May 25 08:55 AM
Rosenbaum David P.	Chief Development Officer	May 23	Sale	3.65	934	3,412	112,162	May 25 08:52 AM
Rosenbaum David P.	Chief Development Officer	Mar 29	Sale	4.63	3,000	13,888	113,096	Mar 31 06:50 PM
RAAB MICHAEL	President & CEO	Feb 21	Sale	3.00	13,449	40,360	896,012	Feb 24 05:39 PM
Rodriguez Susan	Chief Commercial Officer	Feb 21	Sale	3.00	5,586	16,764	355,131	Mar 02 04:36 PM
Renz Justin A	Chief Financial Officer	Feb 21	Sale	3.00	3,439	10,320	336,606	Feb 24 05:37 PM
Rosenbaum David P.	Chief Development Officer	Feb 21	Sale	3.00	3,394	10,185	375,600	Feb 24 05:36 PM
Blanks Robert	See Remarks	Feb 21	Sale	3.00	3,394	10,185	268,969	Feb 24 05:40 PM
Felsch Robert Ora	See Remarks	Feb 21	Sale	3.00	3,214	9,645	114,204	Feb 24 05:38 PM
Williams Laura A	Chief Medical Officer	Feb 21	Sale	3.00	3,187	9,564	319,013	Feb 24 05:41 PM
GRAMMER ELIZABETH A	See Remarks	Feb 21	Sale	3.00	2,914	8,745	329,954	Feb 24 05:39 PM
Rosenbaum David P.	Chief Development Officer	Feb 21	Sale	3.00	1,114	3,343	113,096	Feb 24 05:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARDX

Ardelyx Inc

Upgrade your FINVIZ experience